- Home
- BTAI vs MDAI Comparison
BTAI vs MDAI Comparison
Compare BTAI & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | MDAI |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 48.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTAI | MDAI |
|---|---|---|
| Price | $1.80 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $26.67 | $3.25 |
| AVG Volume (30 Days) | ★ 644.4K | 300.0K |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $752,000.00 | ★ $23,168,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $265.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $1.04 |
| 52 Week High | $8.08 | $3.21 |
Technical Indicators
Market Signals| Indicator | BTAI | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 52.39 |
| Support Level | $1.85 | $1.49 |
| Resistance Level | $2.08 | $1.69 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 38.57 | 51.10 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.